Logo image of BELYS.BR

BELYSSE GROUP NV (BELYS.BR) Stock Fundamental Analysis

Europe - Euronext Brussels - EBR:BELYS - BE0974314461 - Common Stock

0.87 EUR
0 (0%)
Last: 12/5/2025, 7:00:00 PM
Fundamental Rating

3

BELYS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 36 industry peers in the Household Durables industry. BELYS may be in some trouble as it scores bad on both profitability and health. BELYS has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

BELYS had negative earnings in the past year.
In the past year BELYS had a positive cash flow from operations.
BELYS had negative earnings in 4 of the past 5 years.
Of the past 5 years BELYS 4 years had a positive operating cash flow.
BELYS.BR Yearly Net Income VS EBIT VS OCF VS FCFBELYS.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

BELYS's Return On Assets of -0.02% is on the low side compared to the rest of the industry. BELYS is outperformed by 65.71% of its industry peers.
BELYS has a Return On Equity of -0.07%. This is in the lower half of the industry: BELYS underperforms 65.71% of its industry peers.
BELYS has a Return On Invested Capital of 6.45%. This is in the better half of the industry: BELYS outperforms 65.71% of its industry peers.
BELYS had an Average Return On Invested Capital over the past 3 years of 7.13%. This is below the industry average of 9.62%.
Industry RankSector Rank
ROA -0.02%
ROE -0.07%
ROIC 6.45%
ROA(3y)-6.3%
ROA(5y)-7.85%
ROE(3y)-25.25%
ROE(5y)-43.19%
ROIC(3y)7.13%
ROIC(5y)5.99%
BELYS.BR Yearly ROA, ROE, ROICBELYS.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

BELYS has a Operating Margin of 6.91%. This is in the better half of the industry: BELYS outperforms 62.86% of its industry peers.
BELYS's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 61.34%, BELYS belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
In the last couple of years the Gross Margin of BELYS has remained more or less at the same level.
Industry RankSector Rank
OM 6.91%
PM (TTM) N/A
GM 61.34%
OM growth 3Y-5.23%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5YN/A
BELYS.BR Yearly Profit, Operating, Gross MarginsBELYS.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BELYS is destroying value.
Compared to 1 year ago, BELYS has about the same amount of shares outstanding.
The debt/assets ratio for BELYS has been reduced compared to a year ago.
BELYS.BR Yearly Shares OutstandingBELYS.BR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
BELYS.BR Yearly Total Debt VS Total AssetsBELYS.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 0.27, we must say that BELYS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BELYS (0.27) is worse than 85.71% of its industry peers.
BELYS has a debt to FCF ratio of 5.07. This is a neutral value as BELYS would need 5.07 years to pay back of all of its debts.
The Debt to FCF ratio of BELYS (5.07) is better than 68.57% of its industry peers.
A Debt/Equity ratio of 1.80 is on the high side and indicates that BELYS has dependencies on debt financing.
The Debt to Equity ratio of BELYS (1.80) is worse than 91.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.8
Debt/FCF 5.07
Altman-Z 0.27
ROIC/WACC0.59
WACC10.91%
BELYS.BR Yearly LT Debt VS Equity VS FCFBELYS.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

BELYS has a Current Ratio of 1.63. This is a normal value and indicates that BELYS is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BELYS (1.63) is comparable to the rest of the industry.
BELYS has a Quick Ratio of 1.63. This is a bad value and indicates that BELYS is not financially healthy enough and could expect problems in meeting its short term obligations.
BELYS has a Quick ratio of 0.90. This is comparable to the rest of the industry: BELYS outperforms 54.29% of its industry peers.
Industry RankSector Rank
Current Ratio 1.63
Quick Ratio 0.9
BELYS.BR Yearly Current Assets VS Current LiabilitesBELYS.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

2

3. Growth

3.1 Past

The earnings per share for BELYS have decreased strongly by -100.58% in the last year.
BELYS shows a decrease in Revenue. In the last year, the revenue decreased by -6.81%.
BELYS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.43% yearly.
EPS 1Y (TTM)-100.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100.76%
Revenue 1Y (TTM)-6.81%
Revenue growth 3Y0.43%
Revenue growth 5YN/A
Sales Q2Q%-6.97%

3.2 Future

Based on estimates for the next years, BELYS will show a decrease in Earnings Per Share. The EPS will decrease by -1.41% on average per year.
The Revenue is expected to grow by 0.36% on average over the next years.
EPS Next Y-70.83%
EPS Next 2Y-13.4%
EPS Next 3Y-1.41%
EPS Next 5YN/A
Revenue Next Year-3.57%
Revenue Next 2Y-0.54%
Revenue Next 3Y0.36%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BELYS.BR Yearly Revenue VS EstimatesBELYS.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
BELYS.BR Yearly EPS VS EstimatesBELYS.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Forward Earnings ratio is 4.69, which indicates a rather cheap valuation of BELYS.
Based on the Price/Forward Earnings ratio, BELYS is valued cheaply inside the industry as 97.14% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of BELYS to the average of the S&P500 Index (23.69), we can say BELYS is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 4.69
BELYS.BR Price Earnings VS Forward Price EarningsBELYS.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

BELYS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BELYS is cheaper than 94.29% of the companies in the same industry.
BELYS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BELYS is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 1.01
EV/EBITDA 3.98
BELYS.BR Per share dataBELYS.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.4%
EPS Next 3Y-1.41%

0

5. Dividend

5.1 Amount

BELYS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BELYSSE GROUP NV

EBR:BELYS (12/5/2025, 7:00:00 PM)

0.87

0 (0%)

Chartmill FA Rating
GICS IndustryGroupConsumer Durables & Apparel
GICS IndustryHousehold Durables
Earnings (Last)10-20 2025-10-20
Earnings (Next)N/A N/A
Inst Owners12.71%
Inst Owner ChangeN/A
Ins Owners5.56%
Ins Owner ChangeN/A
Market Cap31.27M
Revenue(TTM)270.29M
Net Income(TTM)-55.00K
Analysts84.44
Price Target1.63 (87.36%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)16.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 4.69
P/S 0.12
P/FCF 1.01
P/OCF 0.76
P/B 0.38
P/tB N/A
EV/EBITDA 3.98
EPS(TTM)0
EYN/A
EPS(NY)0.19
Fwd EY21.31%
FCF(TTM)0.86
FCFY99.28%
OCF(TTM)1.14
OCFY130.73%
SpS7.52
BVpS2.28
TBVpS-0.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.02%
ROE -0.07%
ROCE 7.87%
ROIC 6.45%
ROICexc 7.62%
ROICexgc 15.63%
OM 6.91%
PM (TTM) N/A
GM 61.34%
FCFM 11.48%
ROA(3y)-6.3%
ROA(5y)-7.85%
ROE(3y)-25.25%
ROE(5y)-43.19%
ROIC(3y)7.13%
ROIC(5y)5.99%
ROICexc(3y)9.09%
ROICexc(5y)7.47%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)8.69%
ROCE(5y)7.3%
ROICexgc growth 3Y21.04%
ROICexgc growth 5YN/A
ROICexc growth 3Y8.96%
ROICexc growth 5YN/A
OM growth 3Y-5.23%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5YN/A
F-Score4
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity 1.8
Debt/FCF 5.07
Debt/EBITDA 3.85
Cap/Depr 50.25%
Cap/Sales 3.64%
Interest Coverage 1.3
Cash Conversion 106.91%
Profit Quality N/A
Current Ratio 1.63
Quick Ratio 0.9
Altman-Z 0.27
F-Score4
WACC10.91%
ROIC/WACC0.59
Cap/Depr(3y)58.36%
Cap/Depr(5y)60.35%
Cap/Sales(3y)3.69%
Cap/Sales(5y)3.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100.76%
EPS Next Y-70.83%
EPS Next 2Y-13.4%
EPS Next 3Y-1.41%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.81%
Revenue growth 3Y0.43%
Revenue growth 5YN/A
Sales Q2Q%-6.97%
Revenue Next Year-3.57%
Revenue Next 2Y-0.54%
Revenue Next 3Y0.36%
Revenue Next 5YN/A
EBIT growth 1Y-18.87%
EBIT growth 3Y-4.83%
EBIT growth 5YN/A
EBIT Next Year68.18%
EBIT Next 3Y25.03%
EBIT Next 5YN/A
FCF growth 1Y111.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.84%
OCF growth 3YN/A
OCF growth 5YN/A

BELYSSE GROUP NV / BELYS.BR FAQ

What is the fundamental rating for BELYS stock?

ChartMill assigns a fundamental rating of 3 / 10 to BELYS.BR.


What is the valuation status for BELYS stock?

ChartMill assigns a valuation rating of 5 / 10 to BELYSSE GROUP NV (BELYS.BR). This can be considered as Fairly Valued.


Can you provide the profitability details for BELYSSE GROUP NV?

BELYSSE GROUP NV (BELYS.BR) has a profitability rating of 3 / 10.


Can you provide the financial health for BELYS stock?

The financial health rating of BELYSSE GROUP NV (BELYS.BR) is 3 / 10.